Edition:
India

Ergomed PLC (ERGO.L)

ERGO.L on London Stock Exchange

290.00GBp
4:27pm IST
Change (% chg)

-9.00 (-3.01%)
Prev Close
299.00
Open
299.00
Day's High
--
Day's Low
--
Volume
29,314
Avg. Vol
132,998
52-wk High
340.00
52-wk Low
145.00

Latest Key Developments (Source: Significant Developments)

Ergomed Says Revenue, EBITDA For Fy Expected To Be Ahead Of Market Expectations
Monday, 22 Jul 2019 

July 22 (Reuters) - Ergomed PLC ::ERGOMED PLC - ERGOMED H1 2019 TRADING UPDATE.ERGOMED PLC - REVENUE AND EBITDA FOR FULL YEAR 2019 EXPECTED TO BE AHEAD OF MARKET EXPECTATIONS.ERGOMED PLC - STRONG TRADING SEEN ACROSS COMPANY AT START OF YEAR CONTINUED THROUGHOUT FIRST HALF OF 2019.  Full Article

Ergomed Says FY Adj. EBITDA Expected To Be In Line With Market Expectations
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Ergomed PLC ::REVENUES AND EBITDA IN LINE WITH MARKET EXPECTATIONS.SIGNIFICANT TURNAROUND IN PROFITABILITY IN SECOND HALF.NET SERVICE FEE REVENUES FOR 2018 ARE EXPECTED TO BE APPROXIMATELY £46.5 MILLION (2017: £39.6 MILLION).SECOND HALF OF YEAR HAS SEEN STRONG OPERATIONAL PERFORMANCE.FY ADJUSTED EBITDA IS ALSO EXPECTED TO BE IN LINE WITH MARKET EXPECTATIONS.  Full Article

Ergomed Appoints Stuart Jackson As Chief Financial Officer
Monday, 2 Jul 2018 

July 2 (Reuters) - Ergomed Plc ::SAYS APPOINTMENT OF STUART JACKSON AS CHIEF FINANCIAL OFFICER.  Full Article

Ergomed Expects Adjusted EBITDA For 2018 To Be Only Modestly Ahead Of 2017'S Adjusted EBITDA Of £2.8 Million
Thursday, 28 Jun 2018 

June 28 (Reuters) - Ergomed PLC ::EXPECT ADJUSTED EBITDA FOR 2018 TO BE ONLY MODESTLY AHEAD OF 2017'S ADJUSTED EBITDA OF £2.8 MILLION.2018 WILL BE IMPACTED BY DELAYED REVENUES AND LEVEL OF INVESTMENT BEING MADE.  Full Article

Ergomed Names Stephen Stamp As CEO
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Ergomed Plc ::APPOINTMENT OF STEPHEN STAMP AS CEO AND JAN PETRACEK AS CHIEF OPERATING OFFICER AND A BOARD DIRECTOR OF ERGOMED WITH IMMEDIATE EFFECT.DAN WENG HAS DECIDED TO STEP DOWN AS CEO WITH IMMEDIATE EFFECT.  Full Article

Ergomed Says Co-Development Partnership With Allergy Therapeutics
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Ergomed Plc::MULTI-PRODUCT, MULTI-STUDY CO-DEVELOPMENT PARTNERSHIP WITH ALLERGY THERAPEUTICS PLC.COLLABORATION WILL INCLUDE CLINICAL STUDIES, FROM PHASE I - III, OF 3 ORALVAC PRODUCTS: HOUSE DUST MITE; TREE POLLEN; GRASS POLLEN SCHEDULED TO RUN FOR 7 YRS.DEVELOPMENT WILL BEGIN IN 2018 WITH A PHASE I STUDY IN HOUSE DUST MITE.UNDER AGREEMENT, ALLERGY THERAPEUTICS WILL PAY CO A FEE FOR CONDUCTING CLINICAL DEVELOPMENT ACTIVITIES & CO WILL CONTRIBUTE IN-KIND TO DEVELOPMENT COST.ALSO UNDER TERMS, ERGOMED WILL RECEIVE FUTURE TIERED ROYALTIES FOR EACH PRODUCT.  Full Article